NCT02784392View on ClinicalTrials.gov

Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Enteral Feeding Intolerance (EFI)
Interventions
DRUG

Ulimorelin

Active

DRUG

Metoclopramide

Comparator

Trial Locations (5)

Unknown

New Orleans

Columbus

Amsterdam

Barcelona

Madrid

Sponsors
All Listed Sponsors
lead

Lyric Pharmaceuticals

INDUSTRY